Get the Stockscreener App
6.03
1.86%
0.11
Corbus Pharmaceuticals Holdings Inc stock is traded at $6.03, with a volume of 121.61K.
It is up +1.86% in the last 24 hours and down -13.36% over the past month.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
See More
Previous Close:
$5.92
Open:
$5.89
24h Volume:
121.61K
Relative Volume:
0.52
Market Cap:
$70.95M
Revenue:
$1.54M
Net Income/Loss:
$-38.70M
P/E Ratio:
-1.2912
EPS:
-4.67
Net Cash Flow:
$-36.86M
1W Performance:
+5.98%
1M Performance:
-13.36%
6M Performance:
-67.63%
1Y Performance:
-83.77%
1-Day Range:
$5.7801
$6.14
1-Week Range:
$5.68
$6.29
52-Week Range:
$4.64
$61.90
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617-963-0103
Address
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
6.03 | 70.95M | 1.54M | -38.70M | -36.86M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | William Blair | Outperform |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Initiated | Wedbush | Outperform |
| Jul-22-24 | Resumed | H.C. Wainwright | Buy |
| Jun-26-24 | Initiated | B. Riley Securities | Buy |
| Jun-03-24 | Reiterated | Oppenheimer | Outperform |
| May-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-06-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-07-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Mar-26-20 | Initiated | Nomura | Buy |
| Apr-05-19 | Initiated | Jefferies | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-26-18 | Initiated | H.C. Wainwright | Buy |
| Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-18 | Initiated | B. Riley FBR | Buy |
| Jan-19-18 | Initiated | Raymond James | Outperform |
| Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-08-17 | Reiterated | Noble Financial | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
We Think Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Can Afford To Drive Business Growth - Yahoo Finance
Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High? - Yahoo Finance
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
CRBP stock touches 52-week low at $4.64 amid sharp annual decline - Investing.com
CRBP stock touches 52-week low at $4.64 amid sharp annual decline By Investing.com - Investing.com South Africa
Where are the Opportunities in (CRBP) - news.stocktradersdaily.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Analysts Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Target Price at $59.13 - Defense World
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Charles Schwab Investment Management Inc. Purchases 4,239 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
CRBP Stock Plummets to 52-Week Low of $5.65 Amid Market Turbulence By Investing.com - Investing.com South Africa
Corbus begins Phase 1 trial for new obesity treatment CRB-913 By Investing.com - Investing.com South Africa
CRBP Stock Plummets to 52-Week Low of $5.65 Amid Market Turbulence - Investing.com
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity - Quantisnow
Corbus begins Phase 1 trial for new obesity treatment CRB-913 - Investing.com
Corbus Pharmaceuticals Announces First Patient Dosed in - GlobeNewswire
Next-Gen Obesity Drug Shows 50x Better Safety Profile Than Previous Treatments as Clinical Trials Begin - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
(CRBP) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Corbus Pharmaceuticals to reduce board size post-annual meeting By Investing.com - Investing.com Canada
Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Leadership Update - Quantisnow
Corbus Pharmaceuticals to reduce board size post-annual meeting - Investing.com
Corbus Pharmaceuticals Announces Board Member Departure - TipRanks
CRBP stock touches 52-week low at $5.9 amid steep annual decline - Investing.com Australia
CRBP stock touches 52-week low at $5.9 amid steep annual decline By Investing.com - Investing.com South Africa
After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) - Yahoo Finance
After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) - Yahoo Finance
Corbus Pharmaceuticals appoints new COO By Investing.com - Investing.com Australia
Corbus Pharmaceuticals Appoints Ian Hodgson as COO - TipRanks
Corbus Pharmaceuticals appoints new COO - Investing.com
B. Riley Lifts Earnings Estimates for Corbus Pharmaceuticals - Defense World
HC Wainwright Issues Positive Estimate for CRBP Earnings - Defense World
Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target Cut to $53.00 by Analysts at Jefferies Financial Group - MarketBeat
Lifesci Capital Has Optimistic Outlook of CRBP Q1 Earnings - Defense World
What is B. Riley’s Forecast for CRBP Q1 Earnings? - Defense World
Wedbush Reaffirms Outperform Rating for Corbus Pharmaceuticals (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals (NASDAQ:CRBP) Earns “Buy” Rating from HC Wainwright - Defense World
CRBP stock touches 52-week low at $6.53 amid sharp annual decline - Investing.com Australia
CRBP stock touches 52-week low at $6.53 amid sharp annual decline By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):